A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...

Around 200 people with chronic lymphocytic leukaemia (CLL) whose disease has returned after treatment are set to benefit from a new treatment option. Our draft guidance recommends pirtobrutinib (also ...

Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).

We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of ...

There is a simple discount patient access scheme for glofitamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

NICE is unable to make a recommendation on mirabegron (Betmiga) for treating neurogenic detrusor activity in people 3 to 17 years. This is because the company did not provide an evidence submission.

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a commercial access agreement for vanzacaftor-tezacaftor-deutivacaftor. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for erdafitinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for elacestrant. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...